Culture Biosciences and Cytiva to Collaborate on Innovative Upstream Bioprocessing
The bioreactor scaler tool helps scaling between development and manufacturing and to de-risk scaling activities and ensure product quality.
Culture Biosciences and Cytiva announced on June 15, 2023 that they are joining forces to advance innovation in upstream bioprocessing through predictive, robust scale-up capabilities, according to a company press release.
“Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and data produced from our collaborative platform will help them predict performance at the next level, whether it be clinical or commercial scale,” said Nicolas Pivet, head of automation, controls, digital, and learning at Cytiva, in the press release. “You can accelerate the therapeutic process development.”
Cytiva is focusing on their Bioreactor Scaler tool as a first step to feature Culture’s 250 mL bioreactor. Further, the bioreactor scaler tool helps scaling between development and manufacturing and to de-risk scaling activities and ensure product quality.
“We are thrilled by the prospect to advance upstream bioprocess development with a global leader in the development, manufacturing, and delivery of therapeutics,” said Will Patrick, chief executive officer of Culture Biosciences, in a press release. “Digital technologies have greatly advanced other manufacturing sectors in recent years. We look forward to our work with Cytiva to bring similar innovation to upstream bioprocess development, for the benefit of both our customers and their patients.”
Source: Cytiva
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
